Do GLP-1s cause breast cancer?

The short, honest answer

No — not in the evidence we have, which now covers tens of thousands of people across dozens of randomized trials. Two independent analyses looked directly for a breast cancer signal and neither found one.

What that evidence cannot tell you is what happens over twenty years, because nobody has run that study yet. Both of those things are true, and you deserve both rather than only the comfortable one.

Where the fear actually started

This question did not appear from nowhere, and it is worth knowing why, because the answer is reassuring in a way a flat "don't worry" is not.

In the liraglutide development program, women taking the medicine had a higher absolute number of breast cancer events than women who did not. That is a real observation, and chasing it is exactly what regulators are supposed to do.

Then researchers counted properly. Pooled across 52 randomized trials, there were 130 breast cancers among 48,267 people taking a GLP-1, and 107 among 40,755 controls.¹ More cases — from a group about 7,500 people larger. Once you account for how many women were actually in each group, the relative risk is 0.98, which is another way of writing "no difference."

A raw count is not a rate. That single distinction is most of the scare.

What the pooled evidence shows

Both intervals cross 1.0 comfortably in each direction. The honest reading is "no detectable effect either way" — not "protective." The Annals team put the remaining uncertainty in plain numbers: somewhere between 10 fewer and 12 more cases per 10,000 women treated, at moderate certainty.²

The 2021 analysis also looked at benign breast lumps and found no difference there either.¹

The limits, before you feel relieved

• These trials were built to measure weight and blood sugar, not cancer. Cancer events were collected along the way.²
• Follow-up was short. Breast cancers take years to become detectable; a two-year trial cannot see a twenty-year effect.²
• Certainty was graded moderate, by the researchers themselves.²
• A 2025 review reached the same broad position while flagging how much stays open for women who already have a diagnosis.³

If you already have, or have had, breast cancer

This evidence does not speak to you, and it would be wrong of us to imply otherwise. These trials studied women without a cancer diagnosis. That conversation belongs with your oncologist, who knows your history, your treatment and your medications.

What has not changed

A discrete lump, a change on one side only, or anything involving the skin or the nipple still gets looked at — regardless of what any of the numbers above say, and regardless of whether you are losing weight. Gradual, both-sided change while your body is getting smaller is expected. The other list is not, and it does not wait.